URGENT: Seeking Daraxonrasib (RMC-6236) Expanded Access for My Father with KRAS G12D Stage 4 Pancreatic Cancer — India
I am seeking guidance on a legitimate Expanded Access/Compassionate Use pathway for Daraxonrasib (RMC-6236) for my father, who has KRAS G12D-mutated Stage 4 pancreatic adenocarcinoma.
My father was diagnosed with Stage 4 pancreatic adenocarcinoma in April 2025. His tumor molecular/NGS testing has confirmed a KRAS G12D mutation.
Treatment history
April 2025: Diagnosed with Stage 4 pancreatic adenocarcinoma
Molecular profile: KRAS G12D positive
Completed 12 cycles of FOLFIRINOX/FOLFIRI
Subsequently experienced disease progression
Treatment was changed to Gemcitabine
Completed 6 cycles of Gemcitabine
We are now urgently exploring appropriate treatment options following progression.
Why Daraxonrasib (RMC-6236)?
Because his tumor carries the KRAS G12D mutation, we are specifically interested in exploring whether Daraxonrasib (RMC-6236) could be an appropriate option for him.
We understand that RMC-6236 is an investigational therapy, and that eligibility, safety, and access must be assessed by qualified physicians and through the appropriate regulatory and clinical pathways.
We are not seeking to obtain the medicine outside medical supervision or bypass any regulations.
What we are looking for
We are trying to determine whether there is any legitimate way for my father to access RMC-6236 through:
Expanded Access / Compassionate Use
An appropriate clinical trial
A manufacturer-sponsored access program, if available
A patient-assistance or compassionate-access program
Any other legitimate pathway available to an eligible patient from India
Financial situation
We are a family from India and cannot afford the cost of accessing an investigational treatment privately.
Therefore, we are specifically looking for information about no-cost or manufacturer-supported Expanded Access/Compassionate Use, if such a program is available and if my father meets the medical and regulatory criteria.
We are prepared to:
Work directly with his treating oncologist
Provide his complete medical records and NGS report
Undergo any required medical assessments
Complete all regulatory, ethical and institutional requirements
Travel if required for an eligible clinical program
Follow all requirements of the treating institution and study/manufacturer
If you have relevant experience, please help
I would be extremely grateful for information from anyone who has:
Obtained RMC-6236/Daraxonrasib through Expanded Access or Compassionate Use
Information on whether Indian patients can currently access RMC-6236 through an Expanded Access pathway
Knowledge of ongoing or upcoming RMC-6236 trials that may accept patients from India or internationally
Contact information for the relevant manufacturer medical-affairs/clinical-trial or patient-access team
Experience navigating Expanded Access in India
Connections with an oncologist or clinical investigator involved in RMC-6236
Even a contact, email address, clinical-trial reference, or direction to the correct department would be extremely helpful.
We understand that there are no guarantees that RMC-6236 will work, and we understand the risks associated with an investigational treatment. We simply want to determine whether my father has a legitimate opportunity to be evaluated for this treatment.
After exhausting standard treatment options, we are trying everything possible to find another medically appropriate option for him.
If anyone can point us toward the correct Expanded Access program, clinical investigator, hospital, manufacturer contact, or patient-assistance pathway, it would mean a great deal to our family.
Thank you sincerely for reading and for any guidance you can provide. 🙏
Patient: Stage 4 pancreatic adenocarcinoma
Mutation: KRAS G12D positive
Diagnosed: April 2025
Previous treatment: FOLFIRINOX/FOLFIRI → Gemcitabine
Current objective: Explore legitimate access to Daraxonrasib (RMC-6236) through Expanded Access, Compassionate Use, or an appropriate clinical trial
Location: India